New Drugs and Therapies for Alzheimer's Disease

New drugs in development for Alzheimer’s disease have disappointed in recent years. Perhaps this is because the current consensus on the causes of Alzheimer’s disease is wrong? The existing approach to treating the disease follows the ‘amyloid hypothesis’ of which, I will go into more detail later.

 However, since this is an investment focused site, and we are looking for biotech stocks to buy., let’s look at the companies (stock market listed) that are involved in new drug developments for Alzheimer’s disease. I’ve included previous failures in the table, by way of comparison. I’ve previously written about Morphosys in this blog and I hold the stock, even though I don’t proscribe much chance of success for gantenurumab. It has similarities to bapineuzumab, which I think has given weak results so far.

Company	Compound	Action	Status
Forest Laboratories	Neramexane	NMDA receptor antagonist	Failed Phase III 2004
Axonyx	Phenserine	beta amyloid Modulator	Failed Phase III 2005
Neurochem	Alzhemed(tramiprosate)	Inhibits plaque formation	Failed in 2007
Myriad Genetics/Lundbeck	Flurizan(tarenflurbil)	Secretase Modulator	Failed Phase III 2008
Elan/Pfizer/Johnson & Johnson	bapineuzumab	Anti beta amyloid antibody	Phase III Results 2012
Eli Lilly	solaneuzumab	secretase inhibitor	Phase III Completion due 2012
Roche/Morphosys	gantenerumab	Anti beta amyloid antibody	Phase II
Prana Biotechnology	PBT2	Inhibits oligomer formation	Phase IIb

Source: Earnings View, Company Results

The first thing to note is the high degree of failures in Alzheimer’s drugs, this suggests that it is a difficult indication to treat and has a low probability of success for drugs in clinical trials. Perhaps this could be because most of the drugs in development follow the amyloid hypothesis?

Amyloid Hypothesis for Alzheimer’s Disease

Amyloid Precursor Proteins is an integral membrane protein which is concentrated in neuron junctions and, therefore highly present in the brain. When these proteins are engaged in proteolysis they degrade into smaller parts and, one of these parts can be a piece of beta amyloid.

 The ‘Amyloid Hypothesis’ holds it that these pieces are sticky and aggregate together to form oligomers. These oligomers then go on to form sticky plaques which ultimately cause Alzheimer’s disease. They are seen as disrupting and then ultimately destroying brain cells. As outlined above, most of the therapy approaches have involved applying this hypothesis.

Alzheimer’s Drugs in Development

The failures of drugs targeting the plaques that form in the brain have been spectacular. In 2005, Axonyx reported on Phenserine in a 384 patient trial  and stated that "Phenserine showed no statistically significant effect on cognition endpoint ADAS-Cog in each of these two Phase 3 trials."

Neurochem's tramiprosate was intended to be able to inhibit the growth of amyloid accumulation and therefore plaque formulation; however it failed in a 1052 patient Phase III trial in North America. The European trial was discontinued.

The next high profile failure was with Myriad Genetics Flurizan. The drug was intended to inhibit an enzyme responsible for the formulation of amyloid (specifically AB42). Flurizan failed in 1684 patient trial, which was the largest Phase III trial to date. No doubt Lundbeck investors were livid, after having- only recently -bought the co-marketing rights for Europe.


Bapineuzumb Another Failure?

Wyeth (Pfizer) and Elan had previously reported disappointing results in Phase II for bapineuzumab. These results suggested some efficacy in patients who didn't have the APOE4 mutation gene (about 35% of total) but no statistical significance for the remaining 65%  They decided to take it into Phase III and results were due in 2010, however this timeline has been extended to 2012. This is usually a bad sign. Moreover, hopes for this trial were dealt a blow when a study released in the Lancet reported that imaging scans had revealed that bapineuzumab reduced brain plaques by 25% yet had no effect on patients cognitive ability.

The latter point, if confirmed in the trial, will cast serious doubts on the amyloid hypothesis. There is growing disagreement over whether amyloid plaques are the cause or possibly a consequence of Alzheimer's disease. New R & D into the disease could be focused on attaching the oligomers rather than the plaques.

New Therapies in Development for Alzheimer's Disease

Morphosys/Roche gantenerumab, like bapineuzumab, is an anti-amyloid antibody (in early stage trials) and this casts some doubt on its chances of success. Solanezumab is a humanized monoclonal antibody which binds to soluble amyloid beta. It was taken to phase III on the back of safety data, rather than having achieved efficacy in Phase II. Solanezumab is believed to be similar to bapineuzumab but with less toxicity issues. The latter was found to cause brain inflammation in its highest dose in Phase II.

The last of the featured drugs is Prana Biotechnology PBT2 which is entering Phase IIb trials having demonstrated efficacy in a small Phase II trial. It is intended to inhibit the formulation of oligomers. This is interesting because of its focus on oligomers rather than plaques, or plaque reduction.

According to the American Association of Retired Persons (AARP) new research by Dr Sam Gandy is suggesting that the symptoms of Alzheimer's are caused by the oligomers and not the plaques. This conclusion would be consistent with the Lancet published research on bapinezeumab. However, if true, it would cast serious doubt those drugs that are focused on plaque.

Source:

AARP "Alzheimer's A New Theory" AARP Bulletin, September 2010

Lancet Neurology "C-PiB PET assessment of change in fibrillar amyloid beta load in patients with Alzheimer's disease treated with bapineuzumab" Lancet Neurology, Volume 9, Issue 4, Pages 363-372, April 2010

Phenserine Results

PBT2

New Drugs in Development for Rheumatoid Arthritis

I decided to take a look at which new drugs and treatments were in development in order to treat Rheumatoid Arthritis. There are a number of small molecules in development and it is noticeable how Janus kinase (JAK) inhibitors seem to dominate the landscape. Quite a few companies listed on the stock market are developing new drugs for Rheumatoid Arthritis.

TNF Blockers

Unlike TNF blocker biologics like Humira (injected on alternate weeks) Enbrel (injected once a week) or Remicade (intravenous every month or so), these drugs (kinase inhibitors) tend to be taken orally. The three afore mentioned TNF blockers are responsive in 70% of patients, including some who do not respond to the first line treatment of methotrexate. They are expensive and have significant side effects.

JAK Inhibitors for Rheumatoid Arthritis

Janus kinases are receptor associated kinases that provide a pathway for the cytokines that are seen as playing a pivotal role in inflammation of the joints for the Rheumatoid Arthritis sufferer. Of the four JAKs that have been discovered JAK3 has attracted the most attention because it doesn’t seem to have actions outside of hematopoietic cells. I’ll go into more detail on the individual programs below. For reference, the other three JAKs are JAK1, JAK2 and TYK2.

New Drug Pipeline for RA

Company	Compound	Action Inhibitor	Timeline
Lexicon	LX2931	SP1L	Phase IIa ,top line results due by end 2010
Pfizer	CP 690,550	JAK 1/3	Completed Phase III. Four more studies before FDA submission in 2011
Galapagos	GLPG0259	MAPKAPK5	In Phase II, interim results due Q2 2011, top line Q4 2011
Vertex	VX509	JAK 3	In Phase IIa, results due 2011
Morphosys	MOR103	GM-CSF	In Phase Ia/IIb, final results due H1 2012
Incyte/Eli Lilly	INCB28050	JAK 1 / 2	Phase IIb begun in late 2010
Rigel/AstraZeneca	R788	SYK	Phase III begun in late 2010

Pfizer’s CP 690, 550  Tasocitinib

Pfizer’s CP 690 (tasocitinib) is in Phase III for both Rheumatoid Arthritis and Psoriasis. They recently gave Phase III results in Rheumatoid Athritis and it was claimed that CP 690 reduced inflammation in 71 percent of patients. Tasocitinib is an oral indication taken on a once a day regimen. According to the Reuters article

“On the study's first primary goal, 65.7 percent of patients who received 10 milligrams of tasocitinib twice a day achieved ACR20, meaning at least a 20 percent improvement in disease activity and symptoms, after three months of treatment. Nearly 60 percent of 5 mg patients reached ACR20, compared with 26.7 percent of those who received a placebo, researchers said.”

This would appear to be the leader here and Pfizer are developing tasocitinib for other inflammatory diseases such as ulcerative colitis, psoriasis, and Crohn’s disease. FDA submission could take place for RA in 2011.

Interestingly, a study was carried out in 2010 (Cohen) which demonstrated that there weren’t any clinically significant effects on the pharmacokinetics of either drug, if they were taken together. Therefore, there would be no dosage adjustment if taken together.

Rigel/AstraZeneca R788 Fostamatinib Disodium

R788 was in licensed by AstraZeneca early this year in a deal that is potentially worth $1.25bn. This was seen as a significant sign of approval for a drug that had failed one of three Phase II studies in 2009.  R788 or Fostamatinib Disodium is an orally taken (twice a day) SYK inhibitor. Despite the setback in 2009, they reported superb results in a six month Phase IIb study this year. According to Rigel

  “  - The ACR 20 response was achieved by significantly more patients in both the fostamatinib 100mg bid group and the fostamatinib 150mg qd group (67% and 57% respectively) than the placebo group (35%, p<0.001).
- The ACR 50* response rates were 43%, 32% and 19% for the fostamatinib 100mg bid group, 150mg qd group and placebo group respectively (p<0.01). The ACR 70* response rates were 28%, 14% and 10% for the fostamatinib 100mg bid group, 150mg qd group and placebo group respectively (p<0.001 for fostamatinib 100mg bid, p=0.34 for fostamatinib 150 mg qd)
- In addition, the DAS 28 remission rate was significantly higher in both the fostamatinib 100mg bid group and the fostamatinib 150mg qd group (31% and 21% respectively), compared to the placebo group (7%, p<0.01).”

Furthermore, 36 percent of patients achieved ACR20 after just one week, so these phase IIb results demonstrate that R788 has a faster mode of action than Pfizer’s CP 690. Furthermore, remission was statistical significant and this was something that Pfizer could not achieve in Phase III. 

Side effects included increased risk of diarrhoea and hypertension. Phase III trials will begin in late 2010.

Lexicon LX2931 

LX2931 inhibits sphingosine-1-phosphate  (S1P) lyase, which is an enzyme seen as being on a path to regulating the immune system. They’ve demonstrated-in pre-clinical- that inhibiting S1P has reduced inflammation in mice, however the Phase IIa trial is a 208 patient trial. What’s interesting about LX2931 is that it is intended as a combination therapy with methotrexate and is being trialled in this manner. Top line data is due by end 2010.

Incyte/Eli Lilly INCB 28050

Incyte has two JAK inhibitors in development. Its lead compound is INCB18424 which is in Phase III for myelofibrosis and Phase II for polycythemia and psoriasis, respectively.  INCB28050 is its JAK 1 / 2 inhibitor for RA. Eli Lilly paid $90m initially for this compound, with Incyte being eligible for $655m in milestones, as well as royalties on top. They recently presented results for a six month Phase IIa trial

“all three doses of oral INCB28050 (4 mg QD, 7 mg QD and 10 mg QD) improved on the primary endpoint, the percent of patients achieving American College of Rheumatology (ACR) 20 improvement, over the full 24-week treatment period. Importantly, ACR responses improved between week 12 and week 24 achieving up to 72% for ACR20, 44% for ACR50 and 30% for ACR70 at week 24. Results seen at 12 weeks for placebo were 32% for ACR20, 13% for ACR50 and 3% for ACR70, and for patients treated with INCB28050 the results were up to 59% for ACR20, 35% for ACR50 and 16% for ACR70.”
As with Rigel’s R788 adverse effects of diarrhoea and hypertension were reported. Eli Lilly plans to begin Phase IIb shortly. 

Vertex VX509 JAK3 II

I’ve previously discussed Vertex here but omitted to mention VX509. VX509 is a JAK3 inhibitor that Vertex has in a Phase IIa 200 patient proof of concept trial. Interim clinical data is expected in 2011.

Galapagos GLPG0259

Galapagos is another company I mentioned recently and MAPKAPK5 (a protein kinase) was discovered as playing a role in RA, via Galapagos’ proprietary discovery technology. It is a good illustration of their business model. Galapagos feel that it is involved in signaling a pathway to inflammation. GLPG0259 is orally taken, once a day regimen, and is compatible with methotrexate. Indeed, the initiated Phase II will be with methotrexate. Interim results are due in H1 2011 and top line results by end 2011.

Morphosys GSM-CF Inhibitor MOR103

I wrote a bit about MOR103 here and what makes MOR103 a novel antibody, is that it targets GM-CSF, which is seen as an inflammatory mediator that activates the JAK pathway. It is currently in Phase Ib/2a trial, with final results due in H1 2012.

Conclusion on New Treatments for Rheumatoid Arthritis

This new collection of drugs represents a potential improvement to the TNF blockers, in terms of regimen and side effects. Pfizer’s CP 690 is the leader and appears to be a blockbuster in the making. It should be well established by the time that Incyte and Vertex get their JAK inhibitors on the market. Pfizer’s is the only compound successfully through Phase III. Rigel’s R788 is very interesting due to its speed of action and efficacy, however this is yet to be confirmed in Phase III and it will be a while before they complete this. 

Lexicon and Galapagos present options for combination with the first line treatment of methotrexate. GLGP0259 is in early stage, but Lexicon’s LX2931 should give results soon in a Phase II trial. Morphosys MOR103 is early stage but potentially a blockbuster as they own the rights to GSM-CF inhibitors in inflammatory diseases in the US. I opened a small speculative position in Lexicon ahead of their Phase IIa data in LX2931.

Source:

Cohen S, Zwillich SH, Chow V, Labadie RR,Wilkinson B “Co-administration of the JAK inhibitor CP-690,550 and methotrexate is well tolerated in patients with rheumatoid arthritis without need for dose adjustment."  British Journal of Pharmacology, Volume 69, Issue 2, Pages 143-151, February 2010

Reuters “Pfizer Arthritis Drug Succeeds in Late Stage Trial”

Rigel Website (accessed Dec 2010) “Data Published Today Reveal That Novel Oral Therapy Fostamatinib Demonstrates Positive Response in Rheumatoid Arthritis Patients”

Incyte Website (accessed Dec 2010) “Incyte's Selective Oral JAK1 and JAK2 Inhibitor Demonstrates Positive Phase IIa Results in Patients with Active Rheumatoid Arthritis” 

Galapagos NV. An Exciting and Well Balanced Biotech Stock Gives Pipeline Update

Galapagos NV is a Belgium based biotech stock. It is profitable and cash flow positive. Galapagos business model is a combination of selling their drug discovery services (Biofocus and Argenta) to big pharma co's (ex Glaxo SmithKline, Johnson & Johnson, Lilly, Merck and Roche) whilst having a proprietary and partnered development program. As such, they are self funded and sustainable. Thet also have a large-but very early stage-pipeline.

Today they announced that one of the five of their own programmes had successfully completed it's first in human trial. GLPG0429 is a drug in trials for cachexia (weight and muscle mass loss)  but they also believe it could be indicated for Duchenne muscular dystrophy.

This was a Phase I trial intended to demonstrate safety, tolerability and pharmokinetic profiling. No adverse effects were reported. They expect to conduct another Phase I to assess safety and tolerability in 2011, with a proof of concept trial pencilled in for late 2011.

As outlined above, Galapagos has a very early stage pipeline, but this flow of news is positive. Galapagos is a longer term speculative play, whose downisde is limited by their drug discovery services, yet provides good upside potential.

source: http://www.glpg.com/press/2010/43.htm

Vertex Pharmaceuticals and Telaprevir. A protease inhibitor for Hepatitis C.

In the absence of any major news today, I decided to take a look at Vertex Pharmaceuticals VRTX.

In summary,  whilst Vertex is not a binary event biotech company, it’s near term prospects will be guided by one drug, namely Telaprevir for Hepatitis C. This drug is a protease inhibitor, which is a new class of drug that competitors are also trying to develop. Vertex has submitted a New Drug Application for Telaprevir with the FDA.

Vertex Pipeline and Timeline

	Indication	Event	Date
VX 765	Epilepsy	Ph II Top-line data	2010
VX509	Rheumatoid Arthritis	Ph II clinical data	2011
VX 809	Cystic Fibrosis	Ph II with VX 770	2011
VX 770	Cystic Fibrosis	PhIII clinical data	H1 2011
VX 222	Hepatitis C	PhII clinical data	H1 2011
Telaprevir	Hepatitis C	FDA Approval	H1 2011

source: Vertex

By far the most important event is Telaprevir. They filed an NDA in November. Telaprevir is a protease inhibitor and is likely to face future competition from Merck’s Boceprevir (which hasn’t been filed yet). Telaprevir is seen as being more convenient due to it having a shorter treatment duration (12 weeks vs. 24weeks) and also has a high efficacy in treatment of non-responders. It is also possible that Telaprevir could be used as a twice daily regimen.

Whilst Vertex could have the first mover advantage, Boehringer Ingelheim, Bristol Myers Squibb and Roche all have drugs for HCV in development and they are aiming for a once a day regimen. Moreover, Medivir recently announced excellent results in Phase II with their protease inhibitor for HCV.

The good news is that Vertex will likely be a couple of years ahead and shows superiority over its nearest rival Boceprevir. The more circumspect news is that Vertex' NDA filing is the first for this class of drug and assuming quick FDA approval may lead to disappointment. Any delay will hurt Vertex as rivals are in clinical trials. In a sense, buying Vertex would be a 'bet' upon FDA approval and expecting them to maintain a lead against the potential competition.

VX222 is being developed with the last point in mind. It is a polymerase inhibitor that is intended to be used in combination with Telaprevir. As such, it could shorten treatment time and help with efficacy with non-responders.

VX765 is interesting as it the first drug to target epilepsy via anti-inflammation, in this way seizures are believed to be able to be reduced. The upcoming Phase II data will be interesting and provide some upside potential. I would not proscribe a high chance of success with novel drugs in general.

VX770 and VX809 are being trialled in combination for cystic fibrosis. Although the phase II results for VX809 were not great, Vertex feel that-according to their laboratory research-in combination they could be efficacious in cystic fibrosis.

I did not take a position as I suspect that much depends upon Telaprevir approval. Although clearly efficacious,it is the first class of drug and I also see downside when/if Merck decide to file with Boceprevir.



Source:

Medical News Today "Telaprevir May Be Viewed More Positively By Clinicians Than Boceprevir For Hepatitis C Virus Treatment Following Their Launches In 2011"
Bloomberg "Medivir Gains as Early Study Shows Drug Kills Hepatitis C Virus"